Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Luke Walters

Physician Assistant, Medical Mount Vernon, WA Physician Assistant

NPI 1043577562 CMS profile 10440107

2320 Freeway Dr, Mount Vernon, WA 98273

Open in the dashboard

General payments

$4,932

259 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luke Walters of Mount Vernon, WA is reported in the CMS Open Payments database as having received $4,932 across 259 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,925 99
2024 General $1,045 58
2023 General $759 35
2022 General $896 51
2021 General $307 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luke Walters
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Luke Walters were reported at $1,925. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Luke Walters Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $307 $156 $41–$563 $132
2022 $896 $185 $55–$649 $149
2023 $759 $199 $58–$717 $160
2024 $1,045 $206 $62–$740 $164
2025 $1,925 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,224 81 payments
  2. Novartis Pharmaceuticals Corporation $616 30 payments
  3. Lilly USA, LLC $403 19 payments
  4. Genzyme Corporation $381 13 payments
  5. E.R. Squibb & Sons, L.L.C. $304 21 payments
  6. Regeneron Healthcare Solutions, Inc. $265 11 payments
  7. UCB, Inc. $257 9 payments
  8. Janssen Biotech, Inc. $211 8 payments
  9. Pfizer Inc. $211 12 payments
  10. LEO Pharma Inc. $208 10 payments
  11. Other $852 45 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,914 257 payments
  2. Education $18 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $523 17 payments
  2. RINVOQ $442 22 payments
  3. SKYRIZI Immunology $366 25 payments
  4. TALTZ $323 16 payments
  5. SKYRIZI Immunology $312 27 payments
  6. SOTYKTU $304 21 payments
  7. TREMFYA $211 8 payments
  8. EUCRISA $194 11 payments
  9. Bimzelx $179 6 payments
  10. CIBINQO $151 9 payments
  11. Other $2,713 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

810

Median for Physician Assistant: 241

Drug cost

$606,348

Median for Physician Assistant: $4,110

Branded share of claims

14.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 35 $195,583
Rinvoq Upadacitinib Brand 24 $193,167
Taltz Autoinjector Ixekizumab Brand 21 $142,658
Otezla Apremilast Brand 12 $56,001
Clobetasol Propionate Generic 126 $5,171
Tacrolimus Generic 24 $4,859
Ketoconazole Generic 125 $1,484
Triamcinolone Acetonide Generic 145 $1,244
Clindamycin-Benzoyl Peroxide Clindamycin Phos/Benzoyl Perox Brand 14 $1,188
Fluorouracil Generic 17 $1,027

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$33,126

Medicare's payments for the services billed

Medicare patients

261

Average age 73

Services billed

899

144 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 34%
Ischemic heart disease 30%
Chronic kidney disease 22%
Cancer 19%
Heart failure 18%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $174
$174 — —
DUPIXENT
  • GENZYME CORPORATION $139
  • Regeneron Healthcare Solutions, Inc. $28
$167 35 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $142
$142 — —
RINVOQ
  • AbbVie, Inc. $118
$118 24 —
ADBRY
  • LEO Pharma Inc. $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

259 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record